RA
LXRX icon

Royce & Associates’s Lexicon Pharmaceuticals LXRX Stock Holding History

Royce & Associates’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,344
Closed -$18K – 1023
2020
Q3 		$18K Buy
12,344
+1,135
+10% +$2.02K ﹤0.01% 987
2020
Q2 		$22K Buy
11,209
+1,020
+10% +$2K ﹤0.01% 1113
2020
Q1 		$20K Buy
10,189
+4,769
+88% +$14.2K ﹤0.01% 1088
2019
Q4 		$22K Buy
+5,420
New +$20.9K ﹤0.01% 1095
2016
Q2 		– Sell
-340,589
Closed -$4.07M – 1094
2016
Q1 		$4.07M Buy
340,589
+81,000
+31% +$849K 0.03% 671
2015
Q4 		$3.46M Sell
259,589
-74,785
-22% -$919K 0.02% 724
2015
Q3 		$3.59M Sell
334,374
-42,700
-11% -$466K 0.02% 731
2015
Q2 		$3.04M Sell
377,074
-24,902
-6% -$183K 0.01% 858
2015
Q1 		$2.66M Hold
401,976
– – 0.01% 884
2014
Q4 		$2.56M Buy
401,976
+11,100
+3% +$89.5K 0.01% 933
2014
Q3 		$3.86M Sell
390,876
-21,429
-5% -$229K 0.01% 866
2014
Q2 		$4.65M Sell
412,305
-192,543
-32% -$2.07M 0.01% 872
2014
Q1 		$7.33M Hold
604,848
– – 0.02% 775
2013
Q4 		$7.62M Sell
604,848
-22,857
-4% -$364K 0.02% 763
2013
Q3 		$10.4M Hold
627,705
– – 0.03% 642
2013
Q2 		$9.54M Buy
+627,705
New +$9.54M 0.03% 646

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Royce & Associates's LXRX Position: Q4 2020 in Review

Royce & Associates sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2020, closing a stake of 12,344 shares — an estimated $18K sold.

Royce & Associates first reported a position in LXRX in Q2 2013 and held it in 16 quarters. The position peaked at $10.4M in Q3 2013. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2020.

  • Royce & Associates reported no remaining Lexicon Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Royce & Associates sold 12,344 Lexicon Pharmaceuticals shares in Q4 2020, an estimated $18K.
  • Royce & Associates first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Royce & Associates's Lexicon Pharmaceuticals position peaked at $10.4M in Q3 2013.
  • 106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2020.

Based on Royce & Associates's 13F filing for Q4 2020, filed 8 Feb 2021.